Instrument Inactif

Communiqués Sarepta Therapeutics Inc Nasdaq

Actions

US0023461041

Produits pharmaceutiques

Cours en clôture Nasdaq Autres places de cotation
- ^USD	-

22:51	Flash résultats (SRPT) : Sarepta Therapeutics, Inc. publie un chiffre d'affaires de 401,3 millions de dollars au deuxième trimestre, contre 366,4 millions de dollars attendus par le consensus FactSet	MT
29/07	Les conseillers de la FDA votent contre la thérapie de Capricor pour les cardiopathies liées à la myopathie de Duchenne	RE

Communiqués

22:13	Sarepta Therapeutics Announces Second Quarter 2026 Financial Results and Recent Corporate Developments	BU
30/07	Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(4)	AQ
29/07	Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	BU
27/07	Sarepta Therapeutics Appoints Michael Severino, M.D., Chief Executive Officer	BU
22/07	Sarepta Therapeutics to Announce Second Quarter 2026 Financial Results	BU
01/07	Sarepta Announces FDA Acceptance of sNDAs for AMONDYS 45(R) and VYONDYS 53(R)	AQ
30/06	Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	BU
30/06	Sarepta Announces FDA Acceptance of sNDAs for AMONDYS 45® and VYONDYS 53®	BU
01/06	Sarepta Therapeutics to Participate in Upcoming Investor Conferences	BU
13/05	Sarepta Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference	BU
07/05	Sarepta Therapeutics : 1Q 2026 Earnings Results Presentation	PU
06/05	Sarepta Therapeutics: Q1 Earnings Snapshot	AQ
06/05	Sarepta Therapeutics Announces First Quarter 2026 Financial Results and Recent Corporate Developments	BU
22/04	Sarepta Therapeutics to Announce First Quarter 2026 Financial Results	BU
31/03	Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	BU
25/03	Sarepta Therapeutics : Preliminary Phase 1 2 Clinical Data Readout for DM1 and FSHD Programs	PU
25/03	Sarepta Announces First Clinical Data from siRNA Pipeline Targeting FSHD1 and DM1	BU
24/03	Sarepta to Share First Clinical Data from siRNA Pipeline Targeting FSHD1 and DM1	BU
20/03	Sarepta Provides Regulatory Update on AMONDYS 45(R) and VYONDYS 53(R)	AQ
19/03	Sarepta Provides Regulatory Update on AMONDYS 45® and VYONDYS 53®	BU
16/03	Sarepta Announces that Screening and Enrollment are Underway in ENDEAVOR Cohort 8 to Evaluate Enhanced Immunosuppression Regimen as Part of ELEVIDYS Gene Therapy for Non-Ambulant Individuals with Duchenne	BU
11/03	Sarepta Therapeutics : MDA 2026 EMBARK 3yr vs EC Presentation FINAL	PU
08/03	Sarepta Therapeutics : MDA 2026 Pooled Overall Safety Poster & Supplement FINAL	PU
08/03	Sarepta Therapeutics : MDA 2026 EMBARK 3 year vs EC Poster & Supplement FINAL	PU
08/03	Sarepta Therapeutics : MDA 2026 ESSENCE Topline Results Poster and Supplement FINAL	PU